Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways... Show more
The Moving Average Convergence Divergence (MACD) for RVMD turned positive on October 08, 2025. Looking at past instances where RVMD's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where RVMD advanced for three days, in of 297 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 211 cases where RVMD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 18 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 13 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RVMD declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
RVMD broke above its upper Bollinger Band on November 12, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. RVMD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.968) is normal, around the industry mean (24.439). P/E Ratio (0.000) is within average values for comparable stocks, (63.753). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.001). Dividend Yield (0.000) settles around the average of (0.046) among similar stocks. RVMD's P/S Ratio (10000.000) is very high in comparison to the industry average of (322.723).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
an oncology company, which focused on developing novel targeted therapies and engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment.
Industry Biotechnology
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| SBIT | 34.82 | 0.84 | +2.47% |
| ProShares UltraShort Bitcoin ETF | |||
| RODM | 36.49 | 0.19 | +0.52% |
| Hartford Multifactor Dev Mkts (exUS) ETF | |||
| ITAN | 36.31 | 0.11 | +0.29% |
| Sparkline Intangible Value ETF | |||
| BJAN | 53.82 | -0.01 | -0.03% |
| Innovator US Equity Buff ETF™ Jan | |||
| IDEF | 30.88 | -0.14 | -0.47% |
| iShares Defense Industrials Active ETF | |||
A.I.dvisor indicates that over the last year, RVMD has been loosely correlated with NUVL. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if RVMD jumps, then NUVL could also see price increases.
| Ticker / NAME | Correlation To RVMD | 1D Price Change % | ||
|---|---|---|---|---|
| RVMD | 100% | +2.73% | ||
| NUVL - RVMD | 62% Loosely correlated | +0.91% | ||
| OCUL - RVMD | 53% Loosely correlated | +2.41% | ||
| NRIX - RVMD | 53% Loosely correlated | -5.37% | ||
| CGON - RVMD | 52% Loosely correlated | +1.47% | ||
| ROIV - RVMD | 52% Loosely correlated | +2.01% | ||
More | ||||